Advanced Viral Research Corp. Unveils Corporate Website: www.adviral.com; New Site Offers Valuable Resource for Investors, Researchers and the Media.

Health, Business & High Tech Editors

YONKERS, N.Y.--(BW HealthWire)--May 15, 2000

Advanced Viral Research Corp. (OTC BB:ADVR) today unveiled its new corporate Web site at http://www.adviral.com.

The easy-to-navigate site features information on the company, its mission and scientific data on its flagship drug in development, Product R.

Product R is a non-toxic peptide nucleic acid (PNA) immunomodulator, being developed by the company as a broad-spectrum antiviral drug. The drug shows promise for the treatment of viral infections such as AIDS and Human Papilloma Virus (HPV), and autoimmune diseases, such as rheumatoid arthritis. PNAs are stable analogues of genes and have applications as genomics. Advanced Viral Research Corp. laboratory studies have shown that Product R inhibits the production of both the CCR5 and CXCR4 chemokine receptors, the key cellular co-receptors for the human immunodeficiency virus (HIV).

"We can now quickly share our latest news and scientific research findings, on Product R and other therapeutics under development, with members of the scientific and financial communities and the media," said Shalom Z. Hirschman, M.D., President and Chief Executive Officer of Advanced Viral Research Corp. "Our new Web site will be a valuable informational resource as our scientists continue to conduct important research with Product R and as we progress towards our objectives, including filing Investigational New Drug (IND) applications with the FDA."

The new site features links on company history, news releases, basic research findings, results of clinical studies, biographical sketches of key personnel and an overview of the Advanced Viral Research Institute -- where teams of molecular biologists, immunologists and biopolymer chemists conduct biomedical research in an academically oriented environment.

"Future site plans include animated presentations of the Research Institute's scientific findings, such as how viruses attack cells and how Product R helps stimulate cellular responses against viral infections. We will also feature timely commentaries about medical research areas addressed by our scientists," said Dr. Hirschman. "Our Web site will be updated regularly and it will be a premier source of information about our company and its science."

About The Advanced Viral Research Institute

Advanced Viral Research Corp.'s foundation begins with a dedication to scientific research and cutting-edge innovation. In that spirit, the company created The Advanced Viral Research Institute to foster individual scientific inquiry and creativity. Recent successes include identifying Product R's mechanisms of action, which will help with the company's planned IND applications to the FDA.

About Advanced Viral Research Corp.

Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm committed to researching, developing and bringing to market new, effective therapies for viral and other diseases, which will lead to the alleviation of human suffering and diseases worldwide. Its flagship drug, Product R, is a non-toxic immunomodulator that has been shown to have beneficial therapeutic effects against viral diseases such as AIDS.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Product R is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries.